Cite
HARVARD Citation
Pendlebury, A. et al. (2017). Long-term use of pegylated liposomal doxorubicin to a cumulative dose of 4600 mg/m2 in recurrent ovarian cancer. Anti-cancer drugs. 28 (7), p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Pendlebury, A. et al. (2017). Long-term use of pegylated liposomal doxorubicin to a cumulative dose of 4600 mg/m2 in recurrent ovarian cancer. Anti-cancer drugs. 28 (7), p. . [Online].